Keywords:
Abdomen, Contrast agents, Pancreas, CT-Quantitative, Experimental investigations, Treatment effects, Cancer
Authors:
T. H. Perik, E. Van Geenen, E. J. Smit, L. A. A. Brosens, M. W. J. Stommel, E. C. Gootjes, K. J. H. M. Van Laarhoven, H. Huisman, J. J. Hermans; Nijmegen/NL
DOI:
10.26044/ecr2021/C-14092
Results
Using RECIST-criteria patients were classified as 4 responders and 8 non-responders.
Mean blood flow at baseline was 32,7 ml/100g/min (±6,5) in responders and 32,4 ml/100g/min (±12,8) in non-responders (p=0,972). At follow-up BF increased with 25% (±37%) in responders and 0,5% (±33%) in non-responders (p=0,269). Maximum enhancement increased for responders with 45,5% (±36%) and decreased for non-responders with 2,5% (±22%) (p=0,017).
Using area of tumor ROI, patients were classified as 4 responders and 8 non-responders, with however a different distribution compared to the RECIST criteria. Responders showed a mean BF at baseline of 29,5ml/100g/min (±9,0) and non-responders of 34,0ml/100g/min (±11,9) (p=0,526). At follow up BF increased for responders with 40,6% (±24%) and decreased for non-responders with 6% (±29%) (p=0,024). Maximum enhancement increased for responders with 23,6% (±35%) and increased for non-responders with 6,1% (±36%) (p=0,428).